Innovative Strategies in Natural Product Drug Discovery: The Case of Anemoside B4

Engineering ›› 2025, Vol. 54 ›› Issue (11) : 277 -290. DOI: 10.1016/j.eng.2025.06.036

Review

Author information +

History +

Received	Accepted	Published
2025-02-21	2025-06-24	2025-07-10
Issue Date	Revised Date
2025-07-10	2025-06-16

PDF (2454KB)

Abstract

Anemoside B4 (AB4), a triterpenoidal saponin derived from Pulsatilla chinensis, has garnered considerable attention for its potent anti-inflammatory and immunomodulatory activities, culminating in its approval for clinical trials by the Center for Drug Evaluation, National Medical Products Administration, for the treatment of mild to moderate ulcerative colitis. Despite this, AB4’s therapeutic potential remained underexplored until the development of its injection formulation. This review discusses the scientific rationale and theoretical framework behind AB4’s development, offering a new paradigm and innovative research strategy for discovering lead compounds or drug candidates from natural medicines. In-depth investigations into AB4’s cellular targets, biochemical pathways, and administration routes have provided valuable insights into its druggability evaluation and clinical potential. The high water solubility of AB4, attributable to its multiple sugar units, imposes limitations on its bioavailability and pharmacokinetic profiles. To address this, structural modification via chemical methods and enzymatic hydrolysis have been employed, resulting in derivatives with reduced molecular weight, improved bioavailability, enhanced pharmacological activity, and greater clinical potential. These advances lay a solid foundation for the continued development of AB4 and its derivatives as promising therapeutic agents.

Keywords

Anemoside B4 / Discovery process / Anti-inflammation / Immunomodulation / Clinical potential / Structure modification

Cite this article

Download citation ▾

Naixin Kang, Jianping Zhao, Penghao Gao, Yue Lu, Zhong Chen, Xiaoran Li, Ikhlas A. Khan, Shilin Yang, Qiongming Xu, Yanli Liu. Innovative Strategies in Natural Product Drug Discovery: The Case of Anemoside B4. Engineering, 2025, 54(11): 277-290 DOI:10.1016/j.eng.2025.06.036

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Katz L, Baltz RH.Natural product discovery: past, present, and future.J Ind Microbiol Biotechnol 2016; 43(2–3):155-176.

[2]	Chopra B, Dhingra AK.Natural products: a lead for drug discovery and development.Phytother Res 2021; 35(9):4660-4702.

[3]	Ma N, Zhang Z, Liao F, Jiang T, Tu Y.The birth of artemisinin.Pharmacol Ther 2020; 216:e107658.

[4]	Hu YY, He KW, Wang XM.Role of Chinese herbal medicinal ingredients in secretion of cytokines by PCV2-induced endothelial cells.J Immunotoxicol 2016; 13(2):141-147.

[5]	Ye WC, Ji ZN, Tang Y, Wang YX, Wang MS, Zhao SX.A comparison of the effect of some triterpenoids against CCL4-induced hepatic injury in mice.J China Pharma Univ 1996; 07:425-428.

[6]	Kang NX, Shen WH, Zhang Y, Su ZT, Yang SL, Liu YL, et al.Anti-inflammatory and immune-modulatory properties of anemoside B4 isolated from Pulsatilla chinensis in vivo.Phytomedicine 2019; 64:e152934.

[7]	He L, Zhang Y, Kang NX, Wang YE, Zhang ZY, Zha ZX, et al.Anemoside B4 attenuates nephrotoxicity of cisplatin without reducing anti-tumor activity of cisplatin.Phytomedicine 2019; 56:136-146.

[8]	Announcement No.483 of the Ministry of Agriculture and Rural Affairs of the People's Republic of China.Report. Beijing: Ministry of Agriculture and Rural Affairs of the People's Republic of China; 2021. Chinese.

[9]	Announcement No.772 of the Ministry of Agriculture and Rural Affairs of the People's Republic of China.Report. Beijing: Ministry of Agriculture and Rural Affairs of the People's Republic of China; 2024. Chinese.

[10]	Li YH, Zou M, Han Q, Deng LR, Weinshilboum RM.Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis.Pharmacol Res 2020; 160:e105079.

[11]	He MY, Ouyang H, He MZ, Tan T, Li JM, Zhang XY, et al.Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion in the study of anemoside B4, a novel antiviral agent candidate, in rats.Biomed Chromatogr 2017; 31(7):e3914.

[12]	Shen LH, Zhang Y, Shen Y, Su ZT, Yu SM, Cao SZ, et al.Effect of anemoside B4 on milk whey in clinical mastitis-affected cows elucidated using tandem mass tag (TMT)-based quantitative proteomics.Sci Rep 2022; 12(1):e18829.

[13]	Shen LH, Shen Y, Zhang Y, Cao SZ, Yu SM, Zong XL, et al.Effects of anemoside B4 on plasma metabolites in cows with clinical mastitis.Vet Sci 2023; 10(7):e437.

[14]	Nistor M, Rugina D, Diaconeasa Z, Socaciu C, Socaciu MA.Pentacyclic triterpenoid phytochemicals with anticancer activity: updated studies on mechanisms and targeted delivery.Int J Mol Sci 2023; 24(16):e12923.

[15]	Furtado NAJC, Pirson L, Edelberg H, Miranda LM, Loira-Pastoriza C, Preat V, et al.Pentacyclic triterpene bioavailability: an overview of in vitro and in vivo Studies.Molecules 2017; 22(3):e400.

[16]	Ding XJ.Chemical constituents of Pulsatilla chinensis (Bge.) Regel [dissertation]. Su Zhou: Soochow University; 2010. Chinese.

[17]	Zhang ZG, Xu WF, Xu LX, Li GD, Aobulikasimu N, Gao JY, et al.Discovery, preliminary structure–activity relationship, and evaluation of oleanane-type saponins from Pulsatilla chinensis for the treatment of ulcerative colitis.J Med Chem 2023; 66(5):3635-3647.

[18]	Hong KR, Shin JY, Kim JE, Lee SH, Park YL.A case of irritant contact dermatitis associated with Pulsatilla koreana.Ann Dermatol 2019; 31(Suppl):S54-S55.

[19]	Ling Y, Lin ZQ, Zha WJ, Lian T, You SS.Rapid detection and characterisation of triterpene saponins from the root of Pulsatilla chinensis (Bunge) Regel by HPLC-ESI-QTOF-MS/MS.Phytochem Anal 2016; 27(3–4):174-183.

[20]	Liu QC, Wang P, Zhang L, Guo TT, Lv GK, Li YX.Concise synthesis of two natural triterpenoid saponins, oleanolic acid derivatives isolated from the roots of Pulsatilla chinensis.Carbohydr Res 2009; 344(11):1276-1281.

[21]	Gauthier C, Legault J, Lavoie S, Rondeau S, Tremblay S, Pichette A.Synthesis and cytotoxicity of bidesmosidic betulin and betulinic acid saponins.J Nat Prod 2009; 72(1):72-81.

[22]	Shu Z, Chen Z, Liu YL, Zhu WF, Feng YL, Xu QM, et al.A new oleanane-type triterpenoidal saponin from Pulsatilla chinensis.Nat Prod Res 2013; 27(23):2196-2201.

[23]	Xu QM, Shu Z, Zhu WF, Liu YL, Li XR, Yang SL.Lupane-type triterpenoidal saponins from Pulsatilla chinensis and their anticomplement activities through the classical pathway.Planta Med 2013; 79(6):506-512.

[24]	Shu Z.Research on the chemical components of Pulsatilla chinensis [dissertation]. Su Zhou: Soochow University; 2012. Chinese.

[25]	Xu K, Shu Z, Xu QM, Liu YL, Li XR, Wang YL, et al.Cytotoxic activity of Pulsatilla chinensis saponins and their structure–activity relationship.J Asian Nat Prod Res 2013; 15(6):680-686.

[26]	Wu FY, You BG, Tang LH, Wang YD, Mao JJ, Xia C.Determination of pulchinenoside B4 from Pulsatillae Radix.Chin Tradit Pat Med 2011; 33(6):1021-1024.

[27]	Xue SY, Zhou Y, Zhang J, Xiang Z, Liu Y, Miao T, et al.Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Am J Transl Res 2019; 11(4):2580-2589.

[28]	He X, Tang J, Yan HZ, Wang JX, Li HQ, Duan XW, et al.Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through Src-mediated cell apoptosis.Aging 2021; 13(23):25365-25376.

[29]	Xu QM, Shu Z, He WJ, Chen LY, Yang SL, Yang G, et al.Antitumor activity of Pulsatilla chinensis (Bunge) Regel saponins in human liver tumor 7402 cells in vitro and in vivo.Phytomedicine 2012; 19(3–4):293-300.

[30]	Wang LM, Xu QM, Su S, Liu JY, Feng YL, Li XR, et al.Simultaneous purification of pulchinenoside B4 and B5 from Pulsatilla chinensis using macroporous resin and preparative high performance liquid chromatography.Ind Eng Chem Res 2012; 51(45):14859-14866.

[31]	Xu GJ, Yuan CQ, Zhou TY, Pei J.Research on the pharmacognosy identification of the Chinese medicine Pulsatilla chinensis.Acta Pharm Sin B 1956; 1:99-100.

[32]	Zhang QM, Jiang MX, Lv FH.The anti-amoebic effects of several Pulsatilla chinensis besides those from Chuzhou.J Wuhan Univ Med Sci 1958; 1:7-9.

[33]	Shi WJ, Zhou QY, Wang HX, Tan ZJ.Influence of processing at origin on the content of anemoside B4.J Chin Med Mater 2008; 8:1124-1125.

[34]

Liu YL, Song YG, Xu QM, Su D, Feng YL, Li X, et al.Validated rapid resolution LC-ESI-MS/MS method for simultaneous determination of five pulchinenosides from Pulsatilla chinensis (Bunge) Regel in rat plasma: application to pharmacokinetics and bioavailability studies.J Chromatogr B Analyt Technol Biomed Life Sci, 942–943 2013; 141-150.

[35]	Wang JR, Yau LF, Zhang R, Xia Y, Ma J, Ho HM, et al.Transformation of ginsenosides from notoginseng by artificial gastric juice can increase cytotoxicity toward cancer cells.J Agric Food Chem 2014; 62(12):2558-2573.

[36]	Wan JY, Zhang YZ, Yuan JB, Yang FQ, Chen Y, Zhou LD, et al.Biotransformation and metabolic profile of anemoside B4 with rat small and large intestine microflora by ultra-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry.Biomed Chromatogr 2017; 31(5):e3873.

[37]	Lu CS, Zhang XL, Shi J, Wu Y, Li XB.Clinical observation of enema in the treatment of stagnation of damp heat ulcerative colitis retention Pulsatilla Decoction.Clin J Tradit Chin Med 2017; 29(7):1106-1108.

[38]	Song B.Analysis the curative effect of Pulsatilla Decoction in treatment of ulcerative colitis.China Contin Med Edu 2016; 8(16):178-179.

[39]	Gu Z.Efficacy of the Pulsatilla Decoction plus mesalazine on ulcerative colonitis of the shire type.Clin J Chin Med 2018; 10(10):105-106.

[40]	Zhu HX, Ding LS.Study on constituents in sediment of Decoction Pulsatilla.Chin Tradit Pat Med 2002; 24(4):293-296.

[41]	Li B, Shang JC, Zhou QX.Study of total alkaloids from Rhizoma Coptis chinensis on experimental gastric ulcers.Chin J Integr Med 2005; 11(3):217-221.

[42]	Li YM, Liao QF, Lin MN, Zhong DM, Wei L, Han B, et al.An integrated metabonomics and microbiology analysis of host-microbiota metabolic interactions in rats with Coptis chinensis-induced diarrhea.RSC Adv 2015; 5(97):79329-79341.

[43]	Fang LH, Lv Y, Du GH.Progress in study of pharmacological effect of Cortex Fraxini.Chin J Chin Mater Med 2008; 33(23):2732-2736.

[44]	Xie LM.Clinical application of Decoction of Pulsatillae.Beijing J Tradit Chin Med 2005; 24(3):166-167.

[45]	Anderson PM, Sorenson MA.Effects of route and formulation on clinical pharmacokinetics of interleukin-2.Clin Pharmacokinet 1994; 27(1):19-31.

[46]	Gong Q, He LL, Wang ML, Ouyang H, Gao HW, Feng YL, et al.Anemoside B4 protects rat kidney from adenine-induced injury by attenuating inflammation and fibrosis and enhancing podocin and nephrin expression.Evid Based Complement Alternat Med 2019; 2019:e8031039.

[47]	Gong Q, Wang ML, He LL, Feng YL, Yang SL, Du LJ, et al.Protective effect of anemoside B4 from experimental acute renal damage in animal.Mod Chin Med 2019; 21(1):62-67.

[48]	He LL, Gong Q, Yu X, Wang ML, Wong SS, Lei F, et al.Proteomic changes in rat kidney injured by adenine and the regulation of anemoside B4.J Chin Pharm Sci 2019; 28(1):10-20.

[49]	Moudgil KD, Venkatesha SH.The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation.Int J Mol Sci 2022; 24(1):e95.

[50]	Bilia AR, Ballerini R, Qu L, Wang M.Traditional Chinese herbal medicine in European Union: state of art, challenges, and future perspectives focusing on Italian market.Chin Herb Med 2025; 17(1):3-18.

[51]	Su ZT, Xiao JB, Qian BL, Zhu YK, Zhou JJ, Zhu QX, et al.Effect of Pulsatilla saponin B4 on key clinical indexes of dairy cows with clinical mastitis.Chin J Vet Med 2021; 57(8):32-37.

[52]	Wang PJ, Yan J, Wang YL, Su ZT, Zhao JQ, Xu XQ.Clinical effect of Pulsatilla saponin injection for treatment of dairy cows with subclinical mastitis.Chin J Vet Sci 2022; 42(10):2064-2070.

[53]	Dai JL, Yao ZL, Zhang L, Zhang WJ, Zhang Y, Fu HQ, et al.Effect of Pulsatilla saponin B4 on blood routine, serum biochemical and antioxidantfactors in milk of dairy cows with clinical mastitis.J Yangzhou Univ 2022; 43(4):51-57.

[54]	Qian BL, You LC, Zhang Y, Xin Y, lv SK, Xiao JB, et al.Effect of Pulsatilla saponin B4 on somatic cells, enzyme, inflammatory and antioxidant factors in milk of dairy cows with clinical mastitis.Acta Agric Univ Jiangxiensis 2021; 43(4):873-880.

[55]	Lu M, Hu FM, Tu Y, Diao QY.Effects of anemoside B4 on growth performance, nutrition digestion and rumen fermentation of calves.Sci Agric Sin 2023; 56(4):754-765.

[56]	Lu M, Hu FM, Bi YL, Ma T, Diao QY, Jiang LS, et al.Effects of anemoside B4 on diarrhea incidence, serum indices, and fecal microbial of suckling calves.Front Vet Sci 2022; 9:e851865.

[57]	Yang SL, Su ZT.inventors; Guangxi Yingluweite Pharmaceutical Co., Ltd., assignee. Use of Pulsatilla saponin extract in medicine for treating piglet diarrhea. China patent CN202210468783.0. 2022.

[58]	Hu YY, Li B, Li YC, Peng Q, Fan BC, Wang DD, et al.inventors; Jiangsu Academy of Agricultural Sciences, assignee.Drug composition, preparation method and application for anti-porcine epidemic diarrhea virus. China patent CN202211183064.0. 2023.

[59]	Tian XY, Li JY, Liu SY, Dong QL, Fu YJ, Luo RH, et al.Anemoside B4 attenuates necrotic enteritis of laying hens induced by Clostridium perfringens via inhibiting NF-kappaB and PI3K/Akt/mTOR signalling pathways.Heliyon 2024; 10(12):e33161.

[60]	Yang SL.inventor; Chengdu Xinhai Yinglu Biomedical Technology Co., Ltd., assignee. The use of extract from Pulsatilla chinensis extract as an immune adjuvant in the preparation of biological products. China patent CN202310523248.5. 2023.

[61]	Zhang Y, Shen WH, Zha ZX, He Y, Liu YL, Xu QM.Experimental study on pharmacological mechanism of anemoside B4 in ulcerative colitis induced by acetic acid in rats.Anti Infect Pharm 2020; 17(10):1405-1410.

[62]	Liu YL, Zhang Y, Kang NX, Shen WH, Xu QM, Shao P, et al.inventors; Soochow University, assignee.Application of anemoside B4 in the preparation of anti-inflammatory bowel disease drugs. China patent CN201910092465.7. 2019.

[63]	Ma HM, Zhou MJ, Duan WB, Chen LY, Wang LL, Liu P.Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-kappaB/MAPK signaling pathway.Int Immunopharmacol 2020; 87:e106794.

[64]	Feng W, Zhang Y, Zhang YW, Dong Y, Wu JQ, Chen Q, et al.Anemoside B4 ameliorates dextran sulfate sodium (DSS)-induced colitis through inhibiting NLRP3 inflammasome and modulating gut microbiota.Eur J Pharmacol 2024; 963:e176164.

[65]	Han Q, Deng LR, Zou M, Tang HZ, Huang CY, Chen FJ, et al.Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota.Phytomedicine 2022; 106:e154416.

[66]	Liang QH, Li QR, Chen Z, Lv LJ, Lin Y, Jiang HL, et al.Anemoside B4, a new pyruvate carboxylase inhibitor, alleviates colitis by reprogramming macrophage function.Inflamm Res 2024; 73(3):345-362.

[67]	Zhang Y, Zha ZX, Shen WH, Li D, Kang NX, Chen Z, et al.Anemoside B4 ameliorates TNBS-induced colitis through S100A9/MAPK/NF-kappaB signaling pathway.Chin Med 2021; 16(1):e11.

[68]	Yang X, Jia J, Xie XX, Wan MQ, Feng YL, Luo YY, et al.Anemoside B4 regulates fatty acid metabolism reprogramming in mice with colitis-associated cancer.Chin J Chin Mater Med 2023; 48(9):2325-2333.

[69]	Li JL, Yuan RYK, Wang QQ, Feng JF, Gao HW, Yang SL.Therapeutic effect and mechanism of anemoside B4 on imiquimote-induced psoriasis in mice.Drugs Clinic 2022; 37(6):1169-1174.

[70]	Gao HW, Yang SL, Yuan RYK, Li XR, inventors; Guangxi Xinhai Pharmaceutical Technology Co., Ltd., assignee. Use of anemoside B4 in the preparation of drugs for treating or preventing psoriasi. China patent CN202111601109.7. 2022.

[71]	Zou M, Chen FJ, Deng LR, Han Q, Huang CY, Shen SS, et al.Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota.Eur J Pharmacol 2022; 931:e175185.

[72]	Guo CL, Yue YF, Wang BJ, Chen SH, Li D, Zhen FS, et al.Anemoside B4 alleviates arthritis pain via suppressing ferroptosis-mediated inflammation.J Cell Mol Med 2024; 28(4):e18136.

[73]	Ni XH, Wang QQ, Ning YJ, Liu JY, Su Q, Lv S, et al.Anemoside B4 targets NEK7 to inhibit NLRP3 inflammasome activation and alleviate MSU-induced acute gouty arthritis by modulating the NF-κB signaling pathway.Phytomedicine 2025; 138:e156407.

[74]	Liang XW, He J, Gao X, Li JL, Xu ZP, Ni XH, et al.Pharmacodynamic study of Pulsatilla saponin B4 suppository in treatment of gout in rats.Drug Eval Res 2024; 47(7):1466-1474.

[75]	Gong Q, Yin JL, Wang ML, Zha CL, Yu D, Yang SL, et al.Anemoside B4 exerts hypoglycemic effect by regulating the expression of GLUT4 in HFD/STZ rats.Molecules 2023; 28(3):e968.

[76]	Sun KL, He J, Yang M, Yuan RYK, Gao HW, Yang SL.Therapeutic effect and mechanism of Pulsatilla saponin B4 on atherosclerosis of ApoE^−/− mice induced by high fat diet.Drug Eval Res 2024; 47(7):1459-1465.

[77]	Yuan RYK, He J, Huang LT, Du LJ, Gao HW, Xu QM, et al.Anemoside B4 protects against acute lung injury by attenuating inflammation through blocking NLRP3 inflammasome activation and TLR4 dimerization.J Immunol Res 2020; 2020:e7502301.

[78]	He J, Yuan RYK, Cui XL, Cui YS, Han S, Wang QQ, et al.Anemoside B4 protects against Klebsiella pneumoniae- and influenza virus FM1-induced pneumonia via the TLR4/Myd88 signaling pathway in mice.Chin Med 2020; 15:e68.

[79]	Kang NX, Zou Y, Liang QH, Wang YE, Liu YL, Xu GQ, et al.Anemoside B4 inhibits Enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses.Acta Pharmacol Sin 2022; 43(4):977-991.

[80]	Xiao MY, Luo RH, Liang QH, Jiang HL, Liu YL, Xu GQ, et al.Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo.Chin Herb Med 2024; 16(1):106-112.

[81]	Kang NX, Luo YM, Zhao JP, Jiang HL, Xu GQ, Cui NX, et al.Enhancement of MAVS UFMylation and inhibition of lysosomal degradation of MAVS aggregates: new findings on broad-spectrum antiviral mechanism of anemoside B4.Biochem Pharmacol 2025; 239:e117020.

[82]	Shen LH, Luo H, Fan L, Su ZT, Yu SM, Cao SZ, et al.Exploration of the immuno-adjuvant effect and mechanism of anemoside B4 through network pharmacology and experiment verification.Phytomedicine 2024; 124:e155302.

[83]	Gong Q, Wang ML, Jiang Y, Zha CL, Yu D, Lei F, et al.The abrupt pathological deterioration of cisplatin-induced acute kidney injury: emerging of a critical time point.Pharmacol Res Perspect 2021; 9(6):e00895.

[84]	He L, Liu N, Zha ZX, Liang QH, Liu YL, Xu QM.Anemoside B4 alleviates the development of diabetic nephropathy in vitro and in vivo.Rev Bras Farmacogn 2021; 31(3):310-321.

[85]	Zhang CT, Zhang Q, Luo P, Liu J, Zhao WT, Liu XY, et al.Single-cell transcriptomic analysis reveals the alleviating effect of anemoside B4 on murine diabetic nephropathy.Adv Ther 2024; 7(4):e2300379.

[86]	Ma HM, Zhou ZY, Chen LY, Wang LL, Muge Q.Anemoside B4 prevents chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inflammatory response and airway epithelial hyperplasia.Phytomedicine 2022; 107:e154431.

[87]	Seegers H, Fourichon C, Beaudeau F.Production effects related to mastitis and mastitis economics in dairy cattle herds.Vet Res 2003; 34(5):475-491.

[88]	Tong JJ, Sun MW, Zhang H, Yang DL, Zhang YH, Xiong BH, et al.Proteomic analysis of bovine mammary epithelial cells after in vitro incubation with S. agalactiae: potential biomarkers.Vet Res 2020; 51(1):e98.

[89]	Ji JZ, Ding XQ, Liu CL, Dai LL, Yu JT, Li LH, et al.Efficacy and safety of anemoside B4 in canine pneumonia treatment: a prospective, randomized controlled trial.Front Vet Sci 2025; 12:e1530318.

[90]	Olivera P, Danese S, Jay N, Natoli G, Peyrin-Biroulet L.Big data in IBD: a look into the future.Nat Rev Gastroenterol Hepatol 2019; 16(5):312-321.

[91]	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.Lancet 2017; 390(10114):2769-2778.

[92]	Baumgart DC, Le CBerre.Newer biologic and small-molecule therapies for inflammatory bowel disease.N Engl J Med 2021; 385(14):1302-1315.

[93]	Van S Welden, Selfridge AC, Hindryckx P.Intestinal hypoxia and hypoxia-induced signaling as therapeutic targets for IBD.Nat Rev Gastroenterol Hepatol 2017; 14(10):596-611.

[94]	Pucino V, Certo M, Bulusu V, Cucchi D, Goldmann K, Pontarini E, et al.Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4(+) T cell metabolic rewiring.Cell Metab 2019; 30(6):1055-1074.

[95]	Gray LR, Tompkins SC, Taylor EB.Regulation of pyruvate metabolism and human disease.Cell Mol Life Sci 2014; 71(14):2577-2604.

[96]	Qu DD, Shen LL, Liu SQ, Li HC, Ma YZ, Zhang RH, et al.Chronic inflammation confers to the metabolic reprogramming associated with tumorigenesis of colorectal cancer.Cancer Biol Ther 2017; 18(4):237-244.

[97]	Akdis CA.Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?.Nat Rev Immunol 2021; 21(11):739-751.

[98]	Bloom SM, Bijanki VN, Nava GM, Sun LL, Malvin NP, Donermeyer DL, et al.Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease.Cell Host Microbe 2011; 9(5):390-403.

[99]	Zhang Z, Wu XY, Cao SY, Cromie M, Shen YH, Feng YM, et al.Chlorogenic acid ameliorates experimental colitis by promoting growth of Akkermansia in mice.Nutrients 2017; 9(7):e677.

[100]

Aggarwal V, Sunder S, Verma SR.Disease-associated dysbiosis and potential therapeutic role of Akkermansia muciniphila, a mucus degrading bacteria of gut microbiome.Folia Microbiol 2022; 67(6):811-824.

[101]

Teli DM, Gajjar AK.Glycogen synthase kinase-3: a potential target for diabetes.Bioorg Med Chem 2023; 92:e117406.

[102]

Singh V, Aneja S.Pneumonia-management in the developing world.Paediatr Respir Rev 2011; 12(1):52-59.

[103]

Lester SN, Li K.Toll-like receptors in antiviral innate immunity.J Mol Biol 2014; 426(6):1246-1264.

[104]

Lacaille-Dubois MA.Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review.Phytomedicine 2019; 60:e152905.

[105]

Hillmer EJ, Zhang H, Li HS, Watowich SS.STAT3 signaling in immunity.Cytokine Growth Factor Rev 2016; 31:1-15.

[106]

Yoon SY, Kim JS, Jeong KH, Kim SK.Acute kidney injury: biomarker-guided diagnosis and management.Medicina 2022; 58(3):e340.

[107]

Kishi S, Nagasu H, Kidokoro K, Kashihara N.Oxidative stress and the role of redox signaling in chronic kidney disease.Nat Rev Nephrol 2024; 20(2):101-119.

[108]

Cao Z, Niu XB, Wang MH, Yu SW, Wang MK, Mu SL, et al.Anemoside B4 attenuates RANKL-induced osteoclastogenesis by upregulating Nrf2 and dampens ovariectomy-induced bone loss.Biomed Pharmacother 2023; 167:e115454.

[109]

Zhou CQ.Study on the efficacy and pharmacokinetics of anemoside B4 suppository in the treatment of chronic colitis [dissertation]. Nan Chang: Jiangxi University of Traditional Chinese Medicine; 2021. Chinese.

[110]

Guo XZ, Xie Y, Lian S, Li ZX, Gao Y, Xu Z, et al.A sensitive HPLC-MS/MS method for the simultaneous determination of anemoside B4, anemoside A3 and 23-hydroxybetulinic acid: application to the pharmacokinetics and liver distribution of Pulsatilla chinensis saponins.Biomed Chromatogr 2018; 32(3):e4124.

[111]

Yang LR, Meng X, Yu XJ, Kuang HX.Simultaneous determination of anemoside B4, phellodendrine, berberine, palmatine, obakunone, esculin, esculetin in rat plasma by UPLC-ESI-MS/MS and its application to a comparative pharmacokinetic study in normal and ulcerative colitis rats.J Pharm Biomed Anal 2017; 134:43-52.

[112]

Zhang CW, Xu QM, Gao HW, Yuan RYK, Yang SL.Study on pharmacodynamics of anemoside B4 suppository in treatment of rats with hemorrhoid.Drug Eval Res 2022; 45(5):853-863.

[113]

Liu CY, Fu TT, Yang FF, Feng YL, Gao HW, Yang SL, et al.The pulmonary pharmacokinetics and anti-inflammatory effect of anemoside B4 after intratracheal and intravenous administration.Acta Pharm Sin 2022; 57(9):2791-2797.

[114]

Geng MH, Li GF, Li Y, Cui JH, Wang YL, Yang SL.Pharmacokinetics and lung tissue distribution of anemoside B4 in rats.J Guizhou Med Univ 2018; 43(7):745-749.

[115]

Ye YQ, Xue MZ, Tian XT, Gao HW, Hu P, Wang LW, et al.Pharmacokinetic and metabolite profile of orally administered anemoside B4 in rats with an improved exposure in formulations of rectal suppository.J Ethnopharmacol 2023; 315:e116694.

[116]

Gong Q, He LL, Wang ML, Feng YL, Du LJ, Li J, et al.Transmembrane transport of anemoside B4 in HEK293 cells.Modern Chin Med 2024; 26(12):2132-2140.

[117]

Adina-Zada A, Zeczycki TN, Attwood PV.Regulation of the structure and activity of pyruvate carboxylase by acetyl CoA.Arch Biochem Biophys 2012; 519(2):118-130.

[118]

Xu HJ, Ji X, Shi XW, Du YF, Zhu H, Zhang LT.Development of a novel method for triterpenoidal saponins in rat plasma by solid-phase extraction and high-performance liquid chromatography tandem mass spectrometry.Anal Biochem 2011; 419(2):323-332.

[119]

Kim DH.Gut microbiota-mediated pharmacokinetics of ginseng saponins.J Ginseng Res 2018; 42(3):255-263.

[120]

Wan Y, Liu D, Xia J, Xu JF, Zhang L, Yang Y, et al.Ginsenoside CK, rather than Rb1, possesses potential chemopreventive activities in human gastric cancer via regulating PI3K/AKT/NF-kappaB signal pathway.Front Pharmacol 2022; 13:e977539.

[121]

Lipinski CA.Lead- and drug-like compounds: the rule-of-five revolution.Drug Discov Today Technol 2004; 1(4):337-341.

[122]

Xu LK, Deng RX, Feng YH, Yang XR, Zhang WH, Liu P.Chemical constituents from Pulsatillae Radix.Chin J Chin Mater Med 2022; 47(20):5550-5555.

[123]

Love J, Simons CR.Acid hydrolysis of saponins extracted in tincture.PLoS One 2020; 15(12):e0244654.

[124]

Wu ZJ, Ding LS, Zhao SX.Glycosides from Pulsatilla chinensis (Bunge) Regel.J Chin Pharm Univ 1991; 22(5):265-269.

[125]

Lv LJ, Li QR, Wang KX, Zhao JP, Deng KJ, Zhang R, et al.Discovery of a new anti-Inflammatory agent from anemoside B4 derivatives and its therapeutic effect on colitis by targeting pyruvate carboxylase.J Med Chem 2024; 67(9):7385-7405.

[126]

Xu QM, Liu YL, Li H, Xiao LH, inventors; Soochow University.A derivative of anemoside B4 and its preparation method and application.China patent CN202311445100.0. 2024.

[127]

Mei LH, Xu LS, Wu SN, Wang YF, Xu C, Wang L, et al.Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists.Eur J Med Chem 2023; 257:e115472.

[128]

Liu MJ, Wang JS, Shi SS, Gao YF, Zhang YX, Yuan ZY, et al.Optimization, and biological evaluation of 3-O-beta-chacotriosyl betulinic acid amide derivatives as novel small-molecule Omicron.Eur J Med Chem 2023; 256:e115463.

[129]

Takeda S, Ishthara K, Wakui Y, Amagaya S, Maruno M, Akao T, et al.Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis.J Pharm Pharmacol 1996; 48(9):902-905.

[130]

Lee H, Kong G, Park J, Park J.The potential inhibitory effect of ginsenoside Rh2 on mitophagy in UV-irradiated human dermal fibroblasts.J Ginseng Res 2022; 46(5):646-656.

[131]

Del JN Hierro, Casado-Hidalgo G, Reglero G, Martin D.The hydrolysis of saponin-rich extracts from fenugreek and quinoa improves their pancreatic lipase inhibitory activity and hypocholesterolemic effect.Food Chem 2021; 338:e128113.

[132]

Amin HAS, Hanna AG, Mohamed SS.Comparative studies of acidic and enzymatic hydrolysis for production of soyasapogenols from soybean saponin.Biocatal Biotransform 2011; 29(6):311-319.

[133]

Liu YL, Zhou JQ, Xu QM, He W, inventors; Soochow University.A deglycosylated derivative of anemoside B4 and its preparation method and application.China patent CN202410484960.3. 2024.

[134]

Hefny SM, El-Moselhy TF, El-Din N, Ammara A, Angeli A, Ferraroni M, et al.A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments.Eur J Med Chem 2024; 274:e116527.